Find Clinical Trial

Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A 9 week pilot, open labelled, international multicenter study


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

Active substance/
Medical device

S016257, IVABRADINE

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS016257
Protocol CodeCL2-16257-062
EudraCT Code2005-000103-34


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility